

**PERSONAL DATA**

Name: Tom H. Greene  
 Birth Place: Norman, OK  
 Citizenship: United States

**EDUCATION**

<u>Years</u>	<u>Degree</u>	<u>Institution (Area of Study)</u>
1977 - 1980	B.S.	University of Kentucky (Mathematics and Psychology) Lexington, KY
1980 - 1983	M.S.	Cornell University (Statistics) Ithaca, NY
1983 - 1985	Ph.D.	Cornell University (Statistics/ Mathematics and Operation Research Minor) Ithaca, NY

**BOARD CERTIFICATIONS****CURRENT LICENSES/CERTIFICATIONS****ACADEMIC HISTORY****Internal Medicine (Epidemiology)**

10/01/2006 Hire, Tenure Track-Scientist Scholar, Professor

**PROFESSIONAL EXPERIENCE****Full Time Positions**

1985 - 1989 Assistant Professor, University of Kentucky, Department of Statistics, Lexington, KY  
 1989 - 1991 Assistant Professor, MetroHealth Medical Center and Case Western University, Departments of Psychiatry, Epidemiology, and Biostatistics, Cleveland, OH  
 1991 - 1995 Assistant Staff Biostatistician, Cleveland Clinic Foundation, Department of Biostatistics and Epidemiology, Cleveland, OH  
 1995 - 2002 Associate Staff Biostatistician, Cleveland Clinic Foundation, Department of Biostatistics and Epidemiology, Cleveland, OH  
 2002 - 2006 Full Staff Biostatistician, Cleveland Clinic Foundation, Department of Biostatistics and Epidemiology, Cleveland, OH  
 2006 - Present Professor, University of Utah, Division of Clinical Epidemiology, Salt Lake City, UT

**Part Time Positions****Editorial Experience**

2000 - 2005 Editorial Board for Journal of the American Society of Nephrology

**Reviewer Experience**

Reviewer for American Journal of Kidney Diseases  
 Reviewer for Annals of Internal Medicine  
 Reviewer for Archives of Internal Medicine  
 Reviewer for Biometrics  
 Reviewer for Cleveland Clinic Journal of Medicine  
 Reviewer for Controlled Clinical Trials  
 Reviewer for Journal of the American Medical Association

Reviewer for Journal of the American Society of Nephrology  
Reviewer for Journal of the American Statistical Association  
Reviewer for Kidney International  
Reviewer for Medical and Pediatric Oncology  
Reviewer for Neurotoxicology and Teratology  
Reviewer for The International Journal of Psychiatry in Medicine  
Reviewer for Transactions of Mathematical Software

## **SCHOLASTIC HONORS**

## **ADMINISTRATIVE EXPERIENCE**

**Administrative Duties**

**Professional Organization & Scientific Activities**

**Grant Review Committee/Study Section**

**Symposium/Meeting Chair/Coordinator**

## **PROFESSIONAL COMMUNITY ACTIVITIES**

## **UNIVERSITY COMMUNITY ACTIVITIES**

## **SERVICE AT AFFILIATED INSTITUTIONS**

## **SERVICE AT PREVIOUS INSTITUTIONS**

## **CURRENT MEMBERSHIPS IN PROFESSIONAL SOCIETIES**

## **FUNDING**

### **Active Grants**

07/01/94 - 06/30/09 African American Study of Kidney Disease and Hypertension (AASK) Study: Data Coordinating Center  
National Institutes of Health  
Role: Co-Investigator

10/01/02 - 09/30/13 Salt Lake Informatics, Decision Enhancement, and Surveillance (IDEAS) Center  
Principal Investigator: Matthew H. Samore  
VA Health Services Research & Development (HSR&D)  
Role: Co-Investigator

10/01/06 - 05/31/10 Navajo Bone Health Study  
National Institutes of Health  
Role: Co-Investigator

10/01/06 - 08/31/08 Hemo Study  
Direct Costs: \$50,062 Total Costs: \$74,842  
Cleveland Clinic Foundation  
Role: Principal Investigator

10/01/06 - 08/31/08 Focal Glomerulosclerosis Trial  
Cleveland Clinic Foundation  
Role: Principal Investigator

10/01/06 - 08/31/08 Sulodexide In Diabetic Nephropathy  
Keryx Biopharmaceuticals  
Role: Principal Investigator

05/01/07 - 04/30/10 Chronic Kidney Disease Epidemiology Collaboration  
Tufts University  
Role: Principal Investigator

09/01/07 - 08/31/12 Protein Intake, Nutrition, and cardiovascular disease in CKD Stage V  
Principal Investigator: Srinivasan Beddhu  
National Institutes of Health  
Role: Co-Investigator

05/19/08 - 04/30/13 University of Utah Center for Clinical Tranlational Science -CTSA  
National Institutes of Health  
Role: Principal Investigator

01/01/09 - 01/01/09 Analyses For The Krx-0502-201  
Direct Costs: \$31,295 Total Costs: \$39,901  
Keryx Biopharmaceuticals  
Role: Principal Investigator

### **Pending Grants**

01/01/08 - 08/31/08 Hemodialysis (HEMO) Study - Data Coordinating Center  
Cleveland Clinic Foundation  
Role: Principal Investigator

04/01/08 - 08/31/08 Modification of Diet in Renal Disease (MDRD) Study  
Cleveland Clinic Foundation  
Role: Principal Investigator

05/01/09 - 04/30/14 Ckd-Epi  
NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)  
Role: Principal Investigator

09/30/09 - 09/29/14 Chronic Kidney Diseases  
Johns Hopkins University  
Role: Principal Investigator

09/30/09 - 09/29/11 Novel Biomarkers  
Tufts University  
Role: Principal Investigator

12/01/09 - 11/30/14 Medped  
National Institutes of Health  
Role: Principal Investigator

12/01/09 - 11/30/14 Focal Glomerulosclerosis Trial  
Cleveland Clinic Foundation  
Role: Principal Investigator

01/01/10 - 12/31/13 Management Strategies For Lbp  
Agency For Healthcare Research & Quality  
Role: Principal Investigator

04/01/10 - 03/31/12 Multi-State Analysis Of Hemo  
University Of Virginia  
Role: Principal Investigator

04/01/10 - 03/31/15 Markers For Ckd  
Tufts University  
Role: Principal Investigator

### **Past Grants**

07/01/91 - 02/28/92 Alcohol: A behavioral Teratogen in Child Development  
National Institutes of Health  
Role: Co-Investigator

07/01/91 - 04/30/96 Data Coordinating Center for Cooperative Study of Dietary Modification on the Course of  
Progressive Renal Disease  
National Institutes of Health

07/01/91 - 09/30/94 Role: Co-Investigator  
 Coordinating Center for a Comprehensive Evaluation of Diabetic Renal Disease in the Pima Indian Population  
 National Institutes of Health

03/01/92 - 11/30/92 Role: Principal Investigator  
 Tumor Blood Flow After Neutron Radiation  
 National Institutes of Health

04/01/92 - 09/30/94 Role: Co-Investigator  
 Lifestyle and Diabetic Amputation in Pima Indians  
 National Institutes of Health

04/01/92 - 05/31/93 Role: Co-Investigator  
 Biology of Renal Cell Carcinoma  
 National Institutes of Health

09/01/92 - 09/30/94 Role: Co-Investigator  
 Mortality and Morbidity Among Hemodialysis Patients: Pilot Study  
 National Institutes of Health

08/01/93 - 03/31/94 Role: Co-Investigator  
 Effect of Enalapril on Renal Disease  
 MERCK, SHARP, AND DOHME

10/01/95 - 04/28/97 Role: Principal Investigator  
 Baxter Renal Outcome Pilot Study  
 Baxter Healthcare Corporation

04/01/96 - 03/31/00 Role: Co-Investigator  
 Data Coordinating Center for the MDRD Long-Term Follow-up Study  
 National Institutes of Health

09/01/98 - 09/30/01 Role: Co-Investigator  
 Predicting and Improving Outcomes in Acute Renal Failure  
 National Institutes of Health

09/01/02 - 09/30/06 Role: Co-Investigator  
 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trial  
 National Institutes of Health

12/01/03 - 09/30/06 Role: Co-Investigator  
 Frequent Dialysis Network  
 National Institutes of Health

01/01/05 - 09/30/06 Role: Co-Investigator  
 Noninvasive markers and transplant outcome in humans  
 National Institutes of Health

08/01/06 - 07/31/09 Role: Co-Investigator  
 Centers of Excellence in Public Health Informatics  
 Principal Investigator: Matthew H. Samore  
 Centers For Disease Control & Prevention

**Active Contracts**

**Pending Contracts**

**Past Contracts**

**TEACHING RESPONSIBILITIES/ASSIGNMENTS**

**Course and Curriculum Development**

1997 - 2005 Assisted in organization of short courses and presented lectures on epidemiology and statistical methods in renal disease conducted in conjunction with the annual meeting of the American Society of Nephrology

2000 - 2003 Assisted in organizing NIH training program for young researchers and presented lectures in clinical trials in renal disease

### **Courses Directed**

#### **Course Lectures**

1985 - 1989 Instructor, University of Kentucky. Multivariate statistical analysis, Inferential statistics, Regression analysis, Concepts in statistics, Statistics for social scientists.

1992 Instructor, Statistical methods in radiation therapy, Cleveland Clinic Foundation.

1997 - 2002 Instructor, Epidemiological section of curriculum, Ohio State. Medical students training at the Cleveland Clinic.

2008 Primary Instructor, MDCRC 6040(1): Design Clinical Trials, 2 SCH, 1 student, University of Utah, Ctr Clinical & Translational Sci.

2008 Primary Instructor, MDCRC 6040(1): Design Clinical Trials, 10 SCH, 5 students, University of Utah, Ctr Clinical & Translational Sci.

2009 Primary Instructor, FP MD 7110(1): Methods of Clinical Trial, 8 SCH, 4 students, University of Utah, Family and Preventive Medicine.

2009 Primary Instructor, MDCRC 6040(1): Design Clinical Trials, 90 SCH, 5 students, University of Utah, Ctr Clinical & Translational Sci.

### **Clinical Teaching**

#### **Laboratory Teaching**

#### **Small Group Teaching**

#### **Trainee Supervision**

#### **Graduate Student Committees**

1990 - 1992 Member, Suchi Nelson, PhD Committee.

1998 - 2000 Member, Jennifer Gassman, PhD Committee.

2002 - 2004 Member, Guofen Yan, PhD Committee.

2003 - 2005 Member, Edward Mascha, PhD Committee.

### **Educational Lectures**

#### Didactic Lectures

2007 - 2008 Seminars for Nephrology Fellows, University of Utah. 1) Randomized trials and observational studies. 2) Surrogate endpoints.

2007 - 2008 Seminars for University of Utah K-30 program. Writing the statistical section for grant proposal.

### **Continuing Education**

#### CE Courses Taught

1992 - 2000 Lecturer for Dept. of Biostatistics and Epidemiology continuing medical education short course, Cleveland Clinic Foundation

1992 Use of the normal distribution, 2) Nonparametric statistics, 3) Multivariate methods

1994 Use of the normal distribution, 2) Nonparametric statistics, 3) Multivariate methods

1995 Multiple regression and logistic regression

1997 Common statistical distributions, 2) Multiple regression and logistic regression\*

1998 Multiple regression and logistic regression

2000 Simple linear regression, 2) Multiple regression and logistic regression

### **Education Administration**

#### **Other Educational Activities**

### **PEER-REVIEWED JOURNAL ARTICLES**

1. **Greene T, Rayens W.** (1989). Partially pooled covariance matrix estimation in discriminant analysis. *Comm Stat Theor Meth*, 18, 3679-3702.
2. **Greene T.** (1990). The depiction of linear association by matroids. *Comput Stat Data Anal*, 9, 251-269.

3. **Greene T**, Ernhart CB, Martier S, Sokol R, Ager J. (1990 Dec). Prenatal alcohol exposure and language development. *Alcohol Clin Exp Res*, 14(6), 937-45.
4. Rayens W, **Greene T**. (1991). Covariance pooling and stabilization for classification. *Comput Stat Data Anal*, 11, 17-42.
5. **Greene T**. (1991). Descriptively sufficient subcollections of flats in matroids. *Discrete Math*, 87, 149-161.
6. Ernhart CB, **Greene T**. (1991). Low level lead exposure: Language development. *Arch Environ Health*, 45, 342-354.
7. **Greene T**, Ernhart CB, Ager J, Sokol R, Martier S, Boyd T. (1991 Jan-Feb). Prenatal alcohol exposure and cognitive development in the preschool years. *Neurotoxicol Teratol*, 13(1), 57-68.
8. Boyd TA, Ernhart CB, **Greene TH**, Sokol RJ, Martier S. (1991 Jan-Feb). Prenatal alcohol exposure and sustained attention in the preschool years. *Neurotoxicol Teratol*, 13(1), 49-55.
9. **Greene T**, Ernhart CB. (1991). The use of cofactors in pediatric research. *J Dev Behav Pediatr*, 12, 378-385.
10. **Greene T**, Ernhart CB. (1991 Jul-Aug). Prenatal and preschool age lead exposure: relationship with size. *Neurotoxicol Teratol*, 13(4), 417-27.
11. **Greene T**, Ernhart CB, Sokol RJ, Martier S, Marler MR, Boyd TA, Ager J. (1991 Dec). Prenatal alcohol exposure and preschool physical growth: a longitudinal analysis. *Alcohol Clin Exp Res*, 15(6), 905-13.
12. Ernhart CB, **Greene T**. (1992 Jan). Postpartum changes in maternal blood lead concentrations. *Br J Ind Med*, 49(1), 11-3.
13. **Greene T**, Ernhart CB, Boyd TA. (1992 Apr 30). Contributions of risk factors to elevated blood and dentine lead levels in preschool children. *Sci Total Environ*, 115(3), 239-60.
14. Goodkin DE, Rudick RA, Medendorp SV, **Greene T**, Schwetz KM, Fischer J, Daughtry M, Ross J, VanDyke C. (1992). A randomized placebo-controlled double-masked clinical trial of weekly low-dose (7.5 mg) oral methotrexate in chronic progressive MS: Trial design, advantages of using a composite outcome, and observed toxicity. *Online Journal of Current Clinical Trials*, The.
15. **Greene T**, Bourgoignie J, Habwe V, Kusek J, Snetselaar L, Soucie M, Yamamoto M. (1993). Baseline characteristics in the Modification of Diet in Renal Disease Study. *J Am Soc Nephrol*, 4, 1221-1236.
16. Levey AS, **Greene T**, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall PM, Steffes MW, and the Modification of Diet in Renal Disease (MDRD) Study and the Diabetes Control and Complications Trial (DCCT) Research Group. (1993). Glomerular filtration rate measurements in clinical trials. *J Am Soc Nephrol*, 4, 1159-1171.
17. Qu Y, **Greene T**, Piedmonte MR. (1993). Symmetric Bernoulli distributions and generalized binomial distributions. *Biom J*, 5, 523-533.
18. **Greene T**, Ernhart CB. (1993 Apr). Dentine lead and intelligence prior to school entry: a statistical sensitivity analysis. *J Clin Epidemiol*, 46(4), 323-39.
19. **Greene T**, Bourgoignie JJ, Habwe V, Kusek JW, Snetselaar LG, Soucie JM, Yamamoto ME. (1993 Nov). Baseline characteristics in the Modification of Diet in Renal Disease Study. *J Am Soc Nephrol*, 4(5), 1221-36.
20. Coggins CH, Dwyer JT, **Greene T**, Petot G, Snetselaar LG, Van Lente F. (1994 Apr). Serum lipid changes associated with modified protein diets: results from the feasibility phase of the Modification of Diet in Renal Disease Study. *Am J Kidney Dis*, 23(4), 514-23.
21. Mitsumoto H, Ikeda K, Holmlund T, **Greene T**, Cedarbaum JM, Wong V, Lindsay RM. (1994 Aug). The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. *Ann Neurol*, 36(2), 142-8.
22. Ikeda K, Wong V, Holmlund TH, **Greene T**, Cedarbaum JM, Lindsay RM, Mitsumoto H. (1995 Jan). Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease. *Ann Neurol*, 37(1), 47-54.
23. Ikeda K, Klinkosz B, **Greene T**, Cedarbaum JM, Wong V, Lindsay RM, Mitsumoto H. (1995 Apr). Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. *Ann Neurol*, 37(4), 505-11.
24. Peterson JC, Adler S, Burkart JM, **Greene T**, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. (1995 Nov 15). Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. *Ann Intern Med*, 123(10), 754-62.
25. Meyers SM, **Greene T**, Gutman FA. (1995 Dec). A twin study of age-related macular degeneration. *Am J Ophthalmol*, 120(6), 757-66.

26. Ernhart CB, **Greene T**, Sokol RJ, Martier S, Boyd TA, Ager J. (1995 Dec). Neonatal diagnosis of fetal alcohol syndrome: not necessarily a hopeless prognosis. *Alcohol Clin Exp Res*, 19(6), 1550-7.
27. Nelson S, **Greene T**, Ernhart CB. (1996). An epidemiological study of the effects of toxocara-canis infection on cognitive development. *Neurotoxicol Teratol*, 18(2), 167-174.
28. Levey AS, Bosch JP, Coggins CH, **Greene T**, Mitch WE, Schluchter MD, Schwab SJ, Modification of Diet in Renal Disease (MDRD) Study Group. (1996). Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine in the Modification of Diet in Renal Disease Study. *J Am Soc Nephrol*, 7, 556-565.
29. Levey AS, Adler S, Caggiula AW, England BK, **Greene T**, Hunsicker LG, Kusek JW, Rogers NL, Teschan PE, Modification of Diet in Renal Disease (MDRD) Study Group. (1996). Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study. *J Am Soc Nephrol*, 7, 2616-2626.
30. Olencki T, Finke J, Tubbs R, Tuason L, **Greene T**, McLain D, Swanson SJ, Herzog P, Stanley J, Edinger M, Budd GT, Bukowski RM. (1996 Jan). Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy. *J Immunother Emphasis Tumor Immunol*, 19(1), 69-80.
31. Levey AS, Beck GJ, Bosch JP, Caggiula AW, **Greene T**, Hunsicker LG, Klahr S, Modification of Diet in Renal Disease (MDRD) Study Group. (1996). Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. *J Am Soc Nephrol*, 7, 2097-2109.
32. Levey AS, Adler S, Caggiula AW, England BK, **Greene T**, Hunsicker LG, Kusek JW, Rogers NL, Teschan PE. (1996 May). Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. *Am J Kidney Dis*, 27(5), 652-63.
33. Mayfield JA, Reiber GE, Nelson RG, **Greene T**. (1996 Jul). A foot risk classification system to predict diabetic amputation in Pima Indians. *Diabetes Care*, 19(7), 704-9.
34. Lazarus JM, Bourgoignie JJ, Buckalew VM, **Greene T**, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C. (1997 Feb). Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. *Hypertension*, 29(2), 641-50.
35. Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, **Greene T**, Keshaviah PR. (1997 Jun). Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Hemodialysis (HEMO) Study. *Kidney Int*, 51(6), 2013-7.
36. Hunsicker LG, Adler S, Caggiula A, England BK, **Greene T**, Kusek JW, Rogers NL, Teschan PE. (1997 Jun). Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. *Kidney Int*, 51(6), 1908-19.
37. Kopple JD, Levey AS, **Greene T**, Chumlea WC, Gassman JJ, Hollinger DL, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang SR, Zimmer GS. (1997 Sep). Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. *Kidney Int*, 52(3), 778-91.
38. Hebert LA, Kusek JW, **Greene T**, Agodoa LY, Jones CA, Levey AS, Breyer JA, Faubert P, Rolin HA, Wang SR. (1997 Sep). Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. *Hypertension*, 30(3 Pt 1), 428-35.
39. Daugirdas JT, Depner TA, Gotch FA, **Greene T**, Keshaviah P, Levin NW, Schulman G. (1997 Nov). Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. *Kidney Int*, 52(5), 1395-405.
40. Teschan PE, Beck GJ, Dwyer JT, **Greene T**, Klahr S, Levey AS, Mitch WE, Snetelaar LG, Steinman TI, Walser M. (1998 Nov). Effect of a ketoacid-aminoacid-supplemented very low protein diet on the progression of advanced renal disease: a reanalysis of the MDRD feasibility study. *Clin Nephrol*, 50(5), 273-83.
41. Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, **Greene T**, Levin NW, Leypoldt JK. (1999 Jan). Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. *J Am Soc Nephrol*, 10(1), 117-27.
42. **Greene T**, Depner TA, Daugirdas JT. (1999). Mathematical coupling and the relationship between Kt/V and nPCR. *Semin Dial*, 12, 520-528.
43. Depner TA, **Greene T**, Gotch FA, Daugirdas JT, Keshaviah PR, Star RA. (1999 Feb). Imprecision of the hemodialysis dose when measured directly from urea removal. Hemodialysis Study Group. *Kidney Int*, 55(2), 635-47.
44. Levey AS, Bosch JP, Lewis JB, **Greene T**, Rogers N, Roth D. (1999 Mar 16). A more accurate method to estimate

- glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med*, 130(6), 461-70.
45. Daugirdas JT, **Greene T**, Depner TA, Gotch FA, Star RA. (1999 Nov). Relationship between apparent (single-pool) and true (double-pool) urea distribution volume. *Kidney Int*, 56(5), 1928-33.
  46. Kopple JD, **Greene T**, Chumlea WC, Hollinger D, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang SR, Zimmer GS. (2000 Apr). Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. *Kidney Int*, 57(4), 1688-703.
  47. Mayfield JA, Reiber GE, Nelson RG, **Greene T**. (2000 Jun). Do foot examinations reduce the risk of diabetic amputation? *J Fam Pract*, 49(6), 499-504.
  48. **Greene T**, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, Levin NW, Schulman G, Eknoyan G. (2000 Oct). Design and statistical issues of the hemodialysis (HEMO) study. *Controlled Clin Trials*, 21(5), 502-25.
  49. Allon M, Ornt DB, Schwab SJ, Rasmussen C, Delmez JA, **Greene T**, Kusek JW, Martin AA, Minda S. (2000 Nov). Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Hemodialysis (HEMO) Study Group. *Kidney Int*, 58(5), 2178-85.
  50. Schluchter MD, **Greene T**, Beck GJ. (2001 Apr 15). Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease. *Stat Med*, 20(7), 989-1007.
  51. **Greene T**. (2001 Jun). A model for a proportional treatment effect on disease progression. *Biometrics*, 57(2), 354-60.
  52. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, **Greene T**, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S. (2001 Jun 6). Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. *JAMA*, 285(21), 2719-28.
  53. Lewis J, Agodoa L, Cheek D, **Greene T**, Middleton J, O'Connor D, Ojo A, Phillips R, Sika M, Wright J Jr. (2001 Oct). Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. *Am J Kidney Dis*, 38(4), 744-53.
  54. Coresh J, Astor BC, McQuillan G, Kusek J, **Greene T**, Van Lente F, Levey AS. (2002 May). Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. *Am J Kidney Dis*, 39(5), 920-9.
  55. Sarnak MJ, Coronado BE, **Greene T**, Wang SR, Kusek JW, Beck GJ, Levey AS. (2002 May). Cardiovascular disease risk factors in chronic renal insufficiency. *Clin Nephrol*, 57(5), 327-35.
  56. Wright JT Jr, Agodoa L, Contreras G, **Greene T**, Douglas JG, Lash J, Randall O, Rogers N, Smith MC, Massry S. (2002 Jul 22). Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. *Arch Intern Med*, 162(14), 1636-43.
  57. Cheung AK, Yan G, **Greene T**, Daugirdas JT, Dwyer JT, Levin NW, Ornt DB, Schulman G, Eknoyan G. (2002 Sep). Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients. *J Am Soc Nephrol*, 13(9), 2345-52.
  58. Sarnak MJ, Wang SR, Beck GJ, Kusek JW, Selhub J, **Greene T**, Levey AS. (2002 Nov). Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. *Am J Kidney Dis*, 40(5), 932-9.
  59. Wright JT Jr, Bakris G, **Greene T**, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. (2002 Nov 20). Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA*, 288(19), 2421-31.
  60. Sarnak MJ, Poindexter A, Wang SR, Beck GJ, Kusek JW, Marcovina SM, **Greene T**, Levey AS. (2002 Dec). Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. *Kidney Int*, 62(6), 2208-15.
  61. Coresh J, Astor BC, **Greene T**, Eknoyan G, Levey AS. (2003 Jan). Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis*, 41(1), 1-12.
  62. Hebert LA, **Greene T**, Levey A, Falkenhain ME, Klahr S. (2003 May). High urine volume and low urine osmolality are risk factors for faster progression of renal disease. *Am J Kidney Dis*, 41(5), 962-71.

63. Gassman JJ, **Greene T**, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, Douglas J, Jamerson K, Lewis J, Kutner M, Randall OS, Wang SR. (2003 Jul). Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). *J Am Soc Nephrol*, 14(7 Suppl 2), S154-65.
64. Menon V, Wang X, **Greene T**, Beck GJ, Kusek JW, Marcovina SM, Levey AS, Sarnak MJ. (2003 Jul). Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. *Am J Kidney Dis*, 42(1), 44-52.
65. Appel LJ, Middleton J, Miller ER 3rd, Lipkowitz M, Norris K, Agodoa LY, Bakris G, Douglas JG, Charleston J, Gassman J, **Greene T**, Jamerson K, Kusek JW, Lewis JA, Phillips RA, Rostand SG, Wright JT. (2003 Jul). The rationale and design of the AASK cohort study. *J Am Soc Nephrol*, 14(7 Suppl 2), S166-72.
66. Daugirdas JT, **Greene T**, Depner TA, Chumlea C, Rocco MJ, Chertow GM. (2003 Sep). Anthropometrically estimated total body water volumes are larger than modeled urea volume in chronic hemodialysis patients: effects of age, race, and gender. *Kidney Int*, 64(3), 1108-19.
67. Cheung AK, Levin NW, **Greene T**, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G. (2003 Dec). Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. *J Am Soc Nephrol*, 14(12), 3251-63.
68. Kaysen GA, **Greene T**, Daugirdas JT, Kimmel PL, Schulman GW, Toto RD, Levin NW, Yan G. (2003 Dec). Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. *Am J Kidney Dis*, 42(6), 1200-11.
69. Kanagasundaram NS, **Greene T**, Larive AB, Daugirdas JT, Depner TA, Garcia M, Paganini EP. (2003 Dec). Prescribing an equilibrated intermittent hemodialysis dose in intensive care unit acute renal failure. *Kidney Int*, 64(6), 2298-310.
70. Depner TA, **Greene T**, Daugirdas JT, Cheung AK, Gotch FA, Leypoldt JK. (2004 Jan-Feb). Dialyzer performance in the HEMO Study: in vivo K<sub>0</sub>A and true blood flow determined from a model of cross-dialyzer urea extraction. *ASAIO J*, 50(1), 85-93.
71. Daugirdas JT, **Greene T**, Depner TA, Leypoldt J, Gotch F, Schulman G, Star R. (2004 Jan). Factors that affect postdialysis rebound in serum urea concentration, including the rate of dialysis: results from the HEMO Study. *J Am Soc Nephrol*, 15(1), 194-203.
72. Phillips R, Faulkner M, Gassman J, **Greene T**, Jaen L, Kusek J, Lightfoot T, Norris K, Ojo A, Richardson A, Thompson, R, Wang X. (2004). Recruitment of African Americans with chronic renal insufficiency into a multicenter clinical trial: The African American Study of Kidney Disease and Hypertension. *J Clin Hypertens*, 6, 430-6.
73. Menon V, Wang X, **Greene T**, Beck GJ, Kusek JW, Marcovina SM, Levey AS, Sarnak MJ. (2004 Mar). Factors associated with serum leptin in patients with chronic kidney disease. *Clin Nephrol*, 61(3), 163-9.
74. Depner T, Daugirdas J, **Greene T**, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek J, Levin N, Macon E, Milford E, Owen W, Star R, Toto R, Eknoyan G. (2004 Apr). Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. *Kidney Int*, 65(4), 1386-94.
75. Rocco MV, Dwyer JT, Larive B, **Greene T**, Cockram DB, Chumlea WC, Kusek JW, Leung J, Burrowes JD, McLeroy SL, Poole D, Uhlin L. (2004 Jun). The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study. *Kidney Int*, 65(6), 2321-34.
76. Unruh M, Benz R, **Greene T**, Yan G, Beddhu S, DeVita M, Dwyer JT, Kimmel PL, Kusek JW, Martin A, Rehm-McGillicuddy J, Teehan BP, Meyer KB. (2004 Jul). Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. *Kidney Int*, 66(1), 355-66.
77. Leypoldt JK, Cheung AK, Deeter RB, Goldfarb-Rumyantsev A, **Greene T**, Depner TA, Kusek J. (2004 Oct). Kinetics of urea and beta-microglobulin during and after short hemodialysis treatments. *Kidney Int*, 66(4), 1669-76.
78. Lewis J, **Greene T**, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT Jr. (2004 Dec). A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. *J Am Soc Nephrol*, 15(12), 3175-83.
79. Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, **Greene T**, Himmelfarb J, Hunsicker LG, Kaufman JS, Lawson JH, Meyers CM, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI. (2005). Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. *Clinical Trials*, 2(5), 400-12.
80. Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, **Greene T**, Himmelfarb J, Hunsicker LG, Kusek JW,

- Lawson JH, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI. (2005). Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. *Clinical Trials*, 2(5), 413-22.
81. Uhlig K, Wang SR, Beck GJ, Kusek JW, Marcovina SM, **Greene T**, Levey AS, Sarnak MJ. (2005 Jan). Factors associated with lipoprotein(a) in chronic kidney disease. *Am J Kidney Dis*, 45(1), 28-38.
  82. Lea J, **Greene T**, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand S, Miller EP, Smith W, and Bakris GL for the AASK Study Investigators. (2005). Magnitude of Proteinuria Reduction Predicts Risk of End-Stage Renal Disease: Results of the AASK trial. *Arch Intern Med*, 165, 947-953.
  83. Daugirdas JT, **Greene T**. (2005 Mar). Dialysis dose as a determinant of adequacy. *Semin Nephrol*, 25(2), 76-80.
  84. Sarnak MJ, **Greene T**, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS. (2005 Mar 1). The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. *Ann Intern Med*, 142(5), 342-51.
  85. Menon V, Wang X, **Greene T**, Beck GJ, Kusek JW, Selhub J, Levey AS, Sarnak MJ. (2005 Apr). Homocysteine in chronic kidney disease: Effect of low protein diet and repletion with B vitamins. *Kidney Int*, 67(4), 1539-46.
  86. Contreras G, **Greene T**, Agodoa LY, Cheek D, Junco G, Dowie D, Lash J, Lipkowitz M, Miller ER 3rd, Ojo A, Sika M, Wilkening B, Toto RD. (2005 Jul). Blood pressure control, drug therapy, and kidney disease. *Hypertension*, 46(1), 44-50.
  87. Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, Canfield RL, Dietrich KN, Bornschein R, **Greene T**, Rothenberg SJ, Needleman HL, Schnaas L, Wasserman G, Graziano J, Roberts R. (2005 Jul). Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. *Environ Health Perspect*, 113(7), 894-9.
  88. Menon V, **Greene T**, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. (2005 Aug). C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. *Kidney Int*, 68(2), 766-72.
  89. Poggio ED, Nef PC, Wang X, **Greene T**, Van Lente F, Dennis VW, Hall PM. (2005 Aug). Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. *Am J Kidney Dis*, 46(2), 242-52.
  90. Menon V, **Greene T**, Pereira AA, Wang X, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. (2005 Sep). Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. *Am J Kidney Dis*, 46(3), 455-63.
  91. Dwyer JT, Larive B, Leung J, Rocco MV, **Greene T**, Burrowes J, Chertow GM, Cockram DB, Chumlea WC, Daugirdas J, Frydrych A, Kusek JW. (2005 Oct). Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? *Kidney Int*, 68(4), 1766-76.
  92. **Greene T**, Daugirdas J, Depner T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek JW, Levin N, Owen W, Schulman G, Star R, Toto R, Eknoyan G. (2005 Nov). Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". *J Am Soc Nephrol*, 16(11), 3371-80.
  93. Menon V, **Greene T**, Pereira AA, Wang X, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. (2005 Nov). Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. *J Am Soc Nephrol*, 16(11), 3411-7.
  94. Burrowes JD, Larive B, Chertow GM, Cockram DB, Dwyer JT, **Greene T**, Kusek JW, Leung J, Rocco MV. (2005 Dec). Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. *Nephrol Dial Transplant*, 20(12), 2765-74.
  95. Gennari FJ, Hood VL, **Greene T**, Wang X, Levey AS. (2006 Jan). Effect of dietary protein intake on serum total CO2 concentration in chronic kidney disease: Modification of Diet in Renal Disease study findings. *Clin J Am Soc Nephrol*, 1(1), 52-7.
  96. Levey A, Coresh J, **Greene T**, Stevens L, Zhang L, Hendricksen S, Kusek J, Van Lente F. (2006 In Press). Performance of a Revised Modification of Diet in Renal Disease Study Equation to Estimate Glomerular Filtration Rate Using Age, Sex, Race, and Standardized Creatinine Assay. *Ann Intern Med*.
  97. Chertow G, Palevsky P, **Greene T**. (2006 In Press). Studying the Prevention of Acute Kidney Injury: Lessons from an 18th Century Mathematician. *American Society of Nephrology. Clinical Journal*.
  98. Stevens L, **Greene T**, Levey A. (2006 In Press). Surrogate endpoints for clinical trials of kidney disease progression. *American Society of Nephrology. Clinical Journal*.
  99. Stevens L, Coresh J, **Greene T**, Levey A. (2006 In Press). Using GFR estimating equations to assess kidney

- function: Application to chronic kidney disease. *N Engl J Med*.
100. Vonesh EF, **Greene T**, Schluchter MD. (2006 Jan 15). Shared parameter models for the joint analysis of longitudinal data and event times. *Stat Med*, 25(1), 143-63.
  101. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, **Greene T**, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G. (2006 Feb). Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. *J Am Soc Nephrol*, 17(2), 546-55.
  102. Allon M, Daugirdas J, Depner TA, **Greene T**, Ornt D, Schwab SJ. (2006 Mar). Effect of change in vascular access on patient mortality in hemodialysis patients. *Am J Kidney Dis*, 47(3), 469-77.
  103. Ward RA, **Greene T**, Hartmann B, Samtleben W. (2006 Apr). Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. *Kidney Int*, 69(8), 1431-7.
  104. Lash JP, Wang X, **Greene T**, Gadegebeku CA, Hall Y, Jones K, Kusek JW, Sika M, Unruh M. (2006 Jun). Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. *Am J Kidney Dis*, 47(6), 956-64.
  105. 116. Menon V, Li L, Wang X, **Greene T**, Balakrishnan V, Madero M, Pereira A, Beck G, Kusek J, Collins A, Levey A, Sarnak M. (September 2006). Adiponectin and mortality in patients with chronic kidney disease. *J Am Soc Nephrol*, 17(9), 2599-2606.
  106. Chertow GM, Palevsky PM, **Greene T**. (2006 Sep). Studying the prevention of acute kidney injury: lessons from an 18th-century mathematician. *Clin J Am Soc Nephrol*, 1(5), 1124-7.
  107. Norris KC, **Greene T**, Kopple J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang X, Appel LJ. (2006 Oct). Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. *J Am Soc Nephrol*, 17(10), 2928-36.
  108. Wang X, Lewis J, Appel L, Cheek D, Contreras G, Faulkner M, Feldman H, Gassman J, Lea J, Kopple J, Sika M, Toto R, **Greene T**. (2006 Oct). Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. *J Am Soc Nephrol*, 17(10), 2900-9.
  109. 117. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips R, Randall O, Rostand S, Sherer S, Toto R, Wright J, Xuelei W, **Greene T**, Appel L, Lewis J. (November 2006). Cardiovascular outcomes in the african american study of kidney disease and hypertension (AASK) trial. *Am J Kidney Dis*, 48(5), 739-751.
  110. Levey AS, **Greene T**, Sarnak MJ, Wang X, Beck GJ, Kusek JW, Collins AJ, Kopple JD. (2006 Dec). Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. *Am J Kidney Dis*, 48(6), 879-88.
  111. Suri R, Garg A, Chertow G, Levin N, Rocco M, **Greene T**, Beck G, Gassman J, Eggers P, Star R, Ornt D, Klinger A. (February 2007). The Frequent Hemodialysis Network (FHN) randomized trials: Study Design. *Kidney Int*, 71(4), 349-359.
  112. Levey A, Coresh J, **Greene T**, March J, Stevens L, Kusek J, Van Lente F, for the Chronic Kidney Disease Collaboration. (April 2007). Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clin Chem*, 53(4), 766-772.
  113. Menon V, Shlipak M, Wang X, Coresh J, **Greene T**, Stevens L, Kusek J, Beck G, Collins A, Levey A, Sarnak M. (July 2007). Cystatin C as a risk factor for outcomes in chronic kidney disease. *Ann Intern Med*, 147(1), 19-27.
  114. Stevens LA, Manzi J, Levey AS, Chen J, Deysher AE, **Greene T**, Poggio ED, Schmid CH, Steffes MW, Zhang YL, Van Lente F, Coresh J. (2007 Jul). Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. *Am J Kidney Dis*, 50(1), 21-35.
  115. Menon V, Shlipak MG, Wang X, Coresh J, **Greene T**, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS, Sarnak MJ. (2007 Jul 3). Cystatin C as a risk factor for outcomes in chronic kidney disease. *Ann Intern Med*, 147(1), 19-27.
  116. Madero M, Sarnak MJ, Wang X, Scepta CC, **Greene T**, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V. (2007 Sep). Body mass index and mortality in CKD. *Am J Kidney Dis*, 50(3), 404-11.
  117. Castaneda-Scepta C, Sarnak MJ, Wang X, **Greene T**, Madero M, Kusek JW, Beck G, Kopple JD, Levey AS, Menon V. (2007 Sep). Role of adipose tissue in determining muscle mass in patients with chronic kidney disease. *J Ren Nutr (Online)*, 17(5), 314-22.
  118. Samore MH, Shen S, **Greene T**, Stoddard G, Sauer B, Shinogle J, Nebeker J, Harbarth S. (2007 Oct). A simulation-based evaluation of methods to estimate the impact of an adverse event on hospital length of stay. *Med Care*, 45(10 Supl 2), S108-15.

119. Samore MH, Shen S, **Greene T**, Stoddard G, Sauer B, Shinogle J, Nebeker J, Harbarth S. (Oct 2007). A simulation-based evaluation of methods to estimate the impact of an adverse event on hospital length of stay. *Med Care*, 45(10 Supl 2), S108-15.
120. Stevens L, Coresh J, Feldman H, **Greene T**, Lash J, Nelson R, Rahman M, Deysher A, Zhang L, Schmid C, Levey A. (October 2007). Evaluation of the Modification of Diet in Renal Disease Study equation in a large diverse population. *J Am Soc Nephrol*, 18(10), 2749-2757.
121. Stevens LA, Coresh J, Feldman HI, **Greene T**, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, Levey AS. (2007 Oct). Evaluation of the modification of diet in renal disease study equation in a large diverse population. *J Am Soc Nephrol*, 18(10), 2749-57.
122. Beddhu S, Cheung AK, Larive B, **Greene T**, Kaysen GA, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G. (2007 Nov). Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. *J Ren Nutr (Online)*, 17(6), 372-80.
123. Ix JH, Shlipak MG, Sarnak MJ, Beck GJ, **Greene T**, Wang X, Kusek JW, Collins AJ, Levey AS, Menon V. (2007 Dec). Fetuin-A is not associated with mortality in chronic kidney disease. *Kidney Int*, 72(11), 1394-9.
124. Heerspink H, **Greene T**, Lewis J, Raz I, Rohde R, Hunsicker L, Schwartz S, Aronoff S, Katz M, Eisner G, Mersey J, Weigmann T. (December 2007). Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. *Nephrol Dial Transplant*.
125. Garg A, **Greene T**, Levin N. (January 2008). A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. *Nephrol Dial Transplant*, 23(1), 52-55.
126. Rubin MA, Mayer J, **Greene T**, Sauer BC, Hota B, Trick W, Jernigan JA, Samore MH. (2008). An agent-based model for evaluating surveillance methods for catheter-related bloodstream infection. *AMIA Annu Symp Proc*, 631-5.
127. Cheung AK, **Greene T**, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G. (2008 Jan). Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. *Clin J Am Soc Nephrol*, 3(1), 69-77.
128. Kanagasandaram N, **Greene T**, Larive A, Daugirdas J, Depner T, Paganani E. (February 2008). Dosing intermittent haemodialysis in the intensive care unit patient with acute renal failure – estimation of urea removal and evidence for the regional blood flow model. *Nephrol Dial Transplant*.
129. Zhang P, Song PX, Qu A, **Greene T**. (2008 Mar). Efficient estimation for patient-specific rates of disease progression using nonnormal linear mixed models. *Biometrics*, 64(1), 29-38.
130. Zhang P, Song P, Qu A, **Greene T**. (March 2008). Efficient estimation of patient-specific treatment effects on disease progression using non-normal linear mixed models. *Biometrics*, 64(1), 29-38.
131. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, **Greene T**, Levey AS. (2008 Mar). Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. *Am J Kidney Dis*, 51(3), 395-406.
132. Appel L, Wright J, **Greene T**, Kusek J, Lewis J, Wang X, Lipkowitz M, Norris K, Bakris G, Rahman M, Contreras G, Rostand S, Kopple J, Aogodoa L. (April 2008). Long-term effects of rennin-angiotensin-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. *Arch Intern Med*, 168(8), 832-839.
133. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, **Greene T**, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI. (2008 May 14). Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. *JAMA*, 299(18), 2164-71.
134. Heerspink HL, **Greene T**, Lewis JB, Raz I, Rohde RD, Hunsicker LG, Schwartz SL, Aronoff S, Katz MA, Eisner GM, Mersey JH, Wiegmann TB. (2008 Jun). Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. *Nephrol Dial Transplant*, 23(6), 1946-54.
135. Menon V, Wang X, Sarnak MJ, Hunsicker LH, Madero M, Beck GJ, Collins AJ, Kusek JW, Levey AS, **Greene T**. (2008 Jun). Long-term outcomes in nondiabetic chronic kidney disease. *Kidney Int*, 73(11), 1310-5.
136. Li L, **Greene T**. (2008 Jun). Varying coefficients model with measurement error. *Biometrics*, 64(2), 519-26.
137. Kanagasundaram NS, **Greene T**, Larive AB, Daugirdas JT, Depner TA, Paganini EP. (2008 Jul). Dosing intermittent haemodialysis in the intensive care unit patient with acute renal failure--estimation of urea removal and evidence for the regional blood flow model. *Nephrol Dial Transplant*, 23(7), 2286-98.

138. Xie D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, **Greene T**, Hsu CY, Kusek JW, Landis R, Lash J, Levey AS, O'Conner A, Ojo A, Rahman M, Townsend RR, Wang H, Feldman HI. (2008 Sep). A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease. *Clin J Am Soc Nephrol*, 3(5), 1332-8.
139. Daugirdas JT, Depner TA, **Greene T**, Kuhlmann MK, Levin NW, Chertow GM, Rocco MV. (2008 Sep-Oct). Surface-area-normalized Kt/V: a method of rescaling dialysis dose to body surface area-implications for different-size patients by gender. *Semin Dial*, 21(5), 415-21.
140. Unruh ML, Newman AB, Larive B, Dew MA, Miskulin DC, **Greene T**, Beddhu S, Rocco MV, Kusek JW, Meyer KB. (2008 Sep). The influence of age on changes in health-related quality of life over three years in a cohort undergoing hemodialysis. *J Am Geriatr Soc*, 56(9), 1608-17.
141. Yan G, **Greene T**. (2008 Sep 20). Investigating the effects of ties on measures of concordance. *Stat Med*, 27(21), 4190-206.
142. Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, **Greene T**, Appel L, Phillips RA. (2009 Jan). Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. *Hypertension*, 53(1), 20-7.
143. Menon V, Kopple JD, Wang X, Beck GJ, Collins AJ, Kusek JW, **Greene T**, Levey AS, Sarnak MJ. (2009 Feb). Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. *Am J Kidney Dis*, 53(2), 208-17.
144. Stevens LA, Schmid CH, **Greene T**, Li L, Beck GJ, Joffe MM, Froissart M, Kusek JW, Zhang YL, Coresh J, Levey AS. (2009 Mar). Factors other than glomerular filtration rate affect serum cystatin C levels. *Kidney Int*, 75(6), 652-60.
145. **Greene T**. (2009 Mar). Randomized and observational studies in nephrology: how strong is the evidence? *Am J Kidney Dis*, 53(3), 377-88.
146. Madero M, Sarnak MJ, Wang X, **Greene T**, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V. (2009 May). Uric acid and long-term outcomes in CKD. *Am J Kidney Dis*, 53(5), 796-803.
147. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, **Greene T**, Coresh J. (2009 May 5). A new equation to estimate glomerular filtration rate. *Ann Intern Med*, 150(9), 604-12.
148. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, **Greene T**, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI. (2009 May 21). Effect of dipyridamole plus aspirin on hemodialysis graft patency. *N Engl J Med*, 360(21), 2191-201.
149. Young JM, Terrin N, Wang X, **Greene T**, Beck GJ, Kusek JW, Collins AJ, Sarnak MJ, Menon V. (2009 Jun). Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. *Clin J Am Soc Nephrol*, 4(6), 1115-20.
150. Joffe MM, **Greene T**. (2009 Jun). Related causal frameworks for surrogate outcomes. *Biometrics*, 65(2), 530-8.
151. Beddhu S, Nigwekar SU, Ma X, **Greene T**. (2009 Aug). Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. *Nephrol Dial Transplant*, 24(8), 2482-8.
152. Li L, Hu B, **Greene T**. (2009 Sep). A semiparametric joint model for longitudinal and survival data with application to hemodialysis study. *Biometrics*, 65(3), 737-45.
153. Chen QY, Alarcon S, Tharp A, Ahmed OM, Estrella NL, **Greene TA**, Rucker J, Breslin PA. (2009 Sep). Perceptual variation in umami taste and polymorphisms in TAS1R taste receptor genes. *Am J Clin Nutr*, 90(3), 770S-779S.
154. Rogers RK, Stoddard GJ, **Greene T**, Michaels AD, Fernandez G, Freeman A, Nord J, Stehlik J. (2009 Sep 1). Usefulness of adjusting for clinical covariates to improve the ability of B-type natriuretic peptide to distinguish cardiac from noncardiac dyspnea. *Am J Cardiol*, 104(5), 689-94.
155. Beddhu S, Ma X, Baird B, Cheung AK, **Greene T**. (2009 Sep 17). Serum Alkaline Phosphatase and Mortality in African Americans with Chronic Kidney Disease. *Clin J Am Soc Nephrol*. (Epub ahead of print).
156. Stevens LA, Schmid CH, Zhang YL, Coresh J, Manzi J, Landis R, Bakoush O, Contreras G, Genuth S, Klintmalm GB, Poggio E, Rossing P, Rule AD, Weir MR, Kusek J, **Greene T**, Levey AS. (2009 Sep 30). Development and validation of GFR-estimating equations using diabetes, transplant and weight. *Nephrol Dial Transplant*. (Epub ahead of print).
157. Daugirdas JT, Meyer K, **Greene T**, Butler RS, Poggio ED. (2009 Oct). Scaling of measured glomerular filtration

rate in kidney donor candidates by anthropometric estimates of body surface area, body water, metabolic rate, or liver size. *Clin J Am Soc Nephrol*, 4(10), 1575-83.

158. Beddhu S, Baird BC, Zitterkoph J, Neilson J, **Greene T**. (2009 Oct 9). Physical Activity and Mortality in Chronic Kidney Disease (NHANES III). *Clin J Am Soc Nephrol*. (Epub ahead of print).
159. Kevin Rogers R, Stehlik J, Stoddard GJ, **Greene T**, Collins SP, Peacock WF, Maisel AD, Clopton P, Michaels AD. (2009 Nov). Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-IT. *Eur J Heart Fail*, 11(11), 1043-9.
160. Daugirdas JT, Depner TA, **Greene T**, Silisteanu P. (2009 Nov). Solute-solver: a web-based tool for modeling urea kinetics for a broad range of hemodialysis schedules in multiple patients. *Am J Kidney Dis*, 54(5), 798-809.

### **NON PEER-REVIEWED JOURNAL ARTICLES**

1. Li L, **Greene T**. (October 2007). Varying coefficients model with measurement error. *Biometrics*.
2. Beddhu S, Cheung AK, Larive B, **Greene T**, Kaysen GA, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G, Hemodialysis (HEMO) Study Group. (Nov 2007). Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. *J Ren Nutr*, 17(6), 372-80.
3. Cheung AK, **Greene T**, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G, HEMO Study Group. (Jan 2008). Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. *Clin J Am Soc Nephrol*, 3(1), 69-77.

### **REVIEW ARTICLES**

1. Levey AS, **Greene T**, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S. (1999 Nov). Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. [Review]. *J Am Soc Nephrol*, 10(11), 2426-39.
2. **Greene T**. (2000). Are observational studies 'just as effective' as randomized clinical trials?. [Review]. *Blood Purif*, 18(4), 317-22.
3. Paganini EP, Kanagasundaram NS, Larive B, **Greene T**. (2001). Prescription of adequate renal replacement in critically ill patients. [Review]. *Blood Purif*, 19(2), 238-44.
4. **Greene T**. (2005). What did we learn from the HEMO Study? Implications of secondary analyses. [Review]. *Contrib Nephrol*, 149, 69-82.
5. Rocco MV, Cheung AK, **Greene T**, Eknoyan G. (2005 Feb). The HEMO Study: applicability and generalizability. [Review]. *Nephrol Dial Transplant*, 20(2), 278-84.
6. Suri RS, Nesrallah GE, Mainra R, Garg AX, Lindsay RM, **Greene T**, Daugirdas JT. (2006 Jan). Daily hemodialysis: a systematic review. [Review]. *Clin J Am Soc Nephrol*, 1(1), 33-42.
7. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, **Greene T**, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH. (2006 Jan). Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. [Review]. *Clin Chem*, 52(1), 5-18.
8. Stevens LA, **Greene T**, Levey AS. (2006 Jul). Surrogate end points for clinical trials of kidney disease progression. [Review]. *Clin J Am Soc Nephrol*, 1(4), 874-84.
9. Garg AX, **Greene T**, Levin NW. (2008 Jan). A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. [Review]. *Nephrol Dial Transplant*, 23(1), 52-5.

### **BOOKS**

#### **BOOK CHAPTERS**

1. **Greene T**, Lai J, Levey AS. (2001). Interpretation of Clinical Studies of Renal Disease. In Neilson EG, Couser WG (Eds.), *Immunologic Renal Disease* (2nd, pp. 887-914). Philadelphia: Lippincoll-Raven Publishers.
2. **Greene T**, Cheung A, Krediet R. (2002 In Press). Designing Clinical Trials in Dialysis. (5th).

#### **CONFERENCE PROCEEDINGS**

1. **Greene T**, Ernhart CB. (1991). Controlling for measurement error in investigations of the effects of lead on development. *International Conference on Heavy Metals in the Environment*, Edinburgh, Scotland, 131-134.

## OTHER (Commentary/Letters/Editorials/Case Reports/Video/Film)

### **Editorials**

1. Cheung AK, **Greene T.** (2009 Mar). Effect of membrane permeability on survival of hemodialysis patients. *J Am Soc Nephrol*, 20(3), 462-4.

### **Letters**

1. **Greene T**, Ernhart CB. (1993). Response to Letter to the Editor concerning Dentine lead and intelligence prior to school entry: A statistical sensitivity analysis [Letter to the editor]. *J Clin Epidemiol*, 46(4), 404-406.
2. Levey A, **Greene T.** (1999). Prediction equation for glomerular filtration rate – Reply [Letter to the editor]. *Ann Intern Med*, 131, 630.
3. **Greene T**, Appel L, Agodoa L, Wright J. (2003). Antihypertensive drugs and renal protection [Letter to the editor]. *JAMA*, 1102-1103.
4. **Greene T**, Cheung AK, Eknoyan G for the Hemodialysis (HEMO) Study Group. (2003). Response to Scribner BH, Blagg CR, Friedman EA, Hoenich NA, Locatelli F. Effect of dialysis dose and membrane flux in maintenance hemodialysis [Letter to the editor]. *N Engl J Med*, 348, 1491-1493.
5. Hebert LA, **Greene T.** (2004). Proteinuria and blood pressure instead of urine volume are risk factors for progression of renal disease - Reply [Letter to the editor]. *Am J Kidney Dis*, 43(1), 193-194.
6. Sarnak M, Levey A, **Greene T.** (2005). Target blood pressure and kidney disease – Reply [Letter to the editor]. *Ann Intern Med*, 143, 311.
7. Joseph JV, **Greene T.** (2008 Feb). Re: Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1% K. Touijer, F. Rabbani, J. R. Otero, F. P. Secin, J. A. Eastham, P. T. Scardino And B. Guillononau *J Urol* 2007; 178: 120-124 [Letter to the editor]. *J Urol*, 179(2), 789-90.

## PENDING PUBLICATIONS

### **Journal Articles**

1. Dember L, Beck G, Allon M, Delmez J, Dixon B, Greenberg A, Himmelfarb J, Vazquez M, Gassman J, **Greene T**, Radeva M, Braden G, Ikizler A, Rocco M, Davidson I, Kaufman J, Meyers C, Kusek J, Feldman H. (In Press, 2008). Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis. *JAMA*.
2. Yan G, **Greene T.** (In Press, 2008). Investigating the effects of ties on measures of concordance. *Stat Med*.
3. Menon V, Wang X, Sarnak M, Hunsicker L, Madero M, Collins A, Kusek J, Levey A, **Greene T.** (In Press, 2008). Long-term outcomes in nondiabetic kidney disease. *Kidney Int*.
4. Joffe M, **Greene T.** (In press 2008). Related causal frameworks for surrogate outcomes. *Biometrics*.

## RECENTLY PUBLISHED ABSTRACTS (Last 3 Years)

## UNPUBLISHED POSTER PRESENTATIONS

### ORAL PRESENTATIONS

#### **Keynote/Plenary Lectures**

#### **Meeting Presentations (Not Published Abstracts and Not Unpublished Posters)**

##### International

1990	International Society for Environmental Epidemiology
1990 - 1991	International Society for Research on Alcoholism
1991	International Conference on Heavy Metals in the Environment
1994 - 1995	Congress of the European Renal Association, European Dialysis and Transplant Association
1997 - 2005	International Conference of Nephrology
2005	International Vicenza Course on Hemodialysis

##### National

1983 - 2007	American Statistical Association Annual Meetings
-------------	--

1993 - 2007 American Society of Nephrology Annual Meeting  
 1994 - 2007 National Kidney Foundation Annual Meeting  
 1994 - 2003 National Institutes of Health Conferences  
 1994 - 1997 Congress on Nutrition and Metabolism in Renal Disease  
 1994 - 2000 Society for Clinical Trials Annual Meeting  
 1997 Statistical methods in randomized trials  
 1998 Statistical methods in randomized trials Analysis of longitudinal markers of renal disease  
 1999 Development of prediction equations Analysis of longitudinal markers of renal disease  
 2000 Sample size calculations for randomized trials in acute renal failure  
 2000 Statistical issues in studies of vascular access  
 2000 Design of randomized trials in acute renal failure  
 2001 Statistical issues in studies of diabetic renal disease  
 2001 Small and large-scale randomized clinical trials  
 2003 Statistical issues in grant submissions for randomized clinical trials  
 2003 Observational Studies and Randomized Clinical Trials  
 2005 Outcome measures in renal disease: how good are surrogates  
 2005 The great Kt/V debate: Cohort studies vs. randomized clinical trials

Local/Regional

1983 - 1987 Department of Mathematics, Princeton University  
 1985 Cornell University  
 1985 - 1987 Department of Statistics, University of Kentucky  
 1987 Computer Science and Statistics: The 19th Interface  
 1988 - 2005 ENAR Biometrics Meetings  
 1990 - 2003 Cleveland Clinic Foundation  
 1990 Department of Epidemiology, Case Western Reserve University  
 1992 Quantitative Literacy Program, Cleveland Chapter of the American Statistical Association:  
 Presentation on Lead Exposure and Cognitive Development in Children in Cleveland  
 1992 Group Leader for “Fundamentals of Medical Decision Making”, Sessions dealing with statistical  
 inference, correlation and association, and regression methods, Case Western University  
 1993 Lecturer for workshop on grant writing for psychosocial research and oncology; Statistical  
 considerations in research proposals in cancer  
 1994 Conducted workshop in modern statistical methods, Wayne State University. Lectures: 1) multiple  
 regression, 2) Analysis of longitudinal outcomes in clinical trials, 3) Nonparametric regression  
 methods, 4) Error’s in variables regression in epidemiologic studies  
 1997 - 1998 Interdisciplinary Conference on Hypertension in Blacks  
 1997 Ohio Statistics Conference  
 1999 Department of Epidemiology, Case Western Reserve University  
 2001 School of Public Health, Johns Hopkins University  
 2002 Department of Epidemiology, Case Western Reserve University  
 2003 New York Nephrology Conference, Cornell University Medical School  
 2003 Department of Statistics, Case Western Reserve University  
 2003 - 2006 Cleveland Clinic Foundation Nephrology Update  
 2003 Series of two lectures for a course on longitudinal data analysis, graduate level course in Dept. of  
 Epidemiology and Case Western Reserve University  
 2003 Series of six lectures for in-house course in mixed effects models in the Department of Biostatistics  
 and Epidemiology at the Cleveland Clinic  
 2003 Department of Nephrology, Case Western Reserve University  
 2004 Department of Biostatistics, University of Michigan  
 2005 - 2008 Department of Nephrology, University of Utah  
 2005 Midwest Nephrology Conference  
 2006 Lecture for Cleveland Clinic Nephrology Update, Measurement and estimation of GFR: A statistical  
 perspective for nephrologists

2008 - Present Department of Pediatrics, University of Utah

**Invited/Visiting Professor Presentations**

**Grand Rounds Presentations**

**Industrial Presentations**

**Outreach Presentations**

**OTHER SCHOLARLY ACTIVITY**